SI-BONE, Inc. has reported a significant stock transaction involving its Chief Executive Officer, Laura Francis. On October 12, 2026, Francis sold 38,006 shares of the company’s common stock. This transaction is notable as it reflects ongoing changes in leadership and ownership within the company, which could impact investor confidence and the company’s future direction.
Background
SI-BONE, Inc. is a publicly traded company specializing in the design and manufacture of surgical and medical instruments and apparatus. The company is listed on the Nasdaq under the ticker symbol SIBN and is classified under the SIC code 3841. It is categorized as a large accelerated filer and is headquartered in Santa Clara, California.
What the Filing Says
According to the filing made on October 14, 2026, Francis executed the sale as part of a 10b5-1 trading plan established on May 21, 2026. The shares were sold at a weighted-average price of $20.0498, with individual transactions ranging from $20.00 to $20.1050. Following this transaction, Francis retains ownership of 379,256 shares of SI-BONE, Inc.
Impact
This transaction may affect various stakeholders, including investors, employees, and competitors in the surgical and medical instruments sector. The sale of a substantial number of shares by the CEO could signal a shift in confidence or strategy, prompting reactions from investors and analysts alike.
What's Next
The filing does not say what happens next.